Journal
SYNTHETIC BIOLOGY
Volume 7, Issue 1, Pages -Publisher
OXFORD UNIV PRESS
DOI: 10.1093/synbio/ysac001
Keywords
synthetic biology; therapeutics; synthetic biotic medicines
Ask authors/readers for more resources
Advancements in synthetic biology have led to the creation of genetically modified bacteria strains with specific therapeutic benefits, known as synthetic biotics. These engineered living therapeutics show great potential as a novel therapeutic modality, although they face challenges in their development as prescription products.
Advances in synthetic biology have allowed the generation of strains of bacteria that are genetically altered to have specific therapeutic benefits. These synthetic biotics, also widely referred to as engineered living therapeutics, have tremendous potential as a new therapeutic modality, and several have advanced into the clinic and human testing. This review outlines some of the unique attributes of synthetic biotics as well as some of the challenges in their development as prescription products. Regulatory considerations are discussed, and a case study of a program that has advanced into Phase 2 testing is provided: SYNB1618 for the treatment of PKU.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available